sFOLFOXIRI dans le cancer gastro-oesophagien avancé (SAGE)
Une étude de phase II sur le sFOLFOXIRI dans le cancer gastro-œsophagien avancé (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Patrick Boland, MD
- Numéro de téléphone: (732)235-2465
- E-mail: pb564@cinj.rutgers.edu
Lieux d'étude
-
-
New Jersey
-
Hamilton, New Jersey, États-Unis, 08690
- Recrutement
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contact:
- Patrick Boland, MD
-
Lakewood, New Jersey, États-Unis, 08701
- Recrutement
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
Contact:
- Patrick Boland, MD
-
Long Branch, New Jersey, États-Unis, 07740
- Recrutement
- RWJBarnabas Health - Monmouth Medical Center
-
Contact:
- Patrick Boland, MD
-
New Brunswick, New Jersey, États-Unis, 08903
- Recrutement
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Patrick Boland, MD
-
New Brunswick, New Jersey, États-Unis, 08903
- Recrutement
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
-
Contact:
- Patrick Boland, MD
-
Newark, New Jersey, États-Unis, 07112
- Recrutement
- RWJBarnabas Health - Newark Beth Israel Medical Center
-
Contact:
- Patrick Boland, MD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
-
Tumor is HER2 negative by standard local testing methodology
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
-
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
-
No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable
o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
-
At least 18 years of age
-
Adequate bone marrow and organ functions as defined by:
-
Absolute neutrophil count ≥ 1500 cells/ μL
-
Hemoglobin ≥ 8 g/ dL
-
Platelets > 100,000 / μL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
-
Total bilirubin ≤ ULN
-
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
-
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
-
Ability to understand the nature of this study protocol and give written informed consent.
-
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- For those patients who are going to receive nivolumab
- No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
- Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
- Prior organ transplant or bone marrow transplant
- History of interstitial lung disease or pneumonitis
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
- Major surgery within the four weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Autre: 4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),
A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:
|
This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC). The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux d'événements indésirables
Délai: Trois ans
|
Trois ans
|
|
|
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
Délai: Three Years
|
To determine the clinical efficacy of treatment regimen in terms of objective response rate. |
Three Years
|
|
Progression Free Survival (PFS)
Délai: Three Years
|
To determine the clinical efficacy of the study treatment in terms of progressive free survival. |
Three Years
|
|
Overall Survival (OS)
Délai: Three Years
|
To determine the clinical efficacy of the study treatment in terms of overall survival. |
Three Years
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Patrick Boland, MD, Rutgers Cancer Institute of New Jersey
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 072204
- Pro2022000268 (Autre identifiant: Rutgers Cancer Institute of New Jersey)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .